Seeking Alpha

Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody...

Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody program and will establish preclinical development capabilities in-house instead of using third parties. The firm will take on $8M in funding from Israel-based Baize Investments to help move along its research program.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs